Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 15,09100Cr 9.82TCr 8.31TCr 7.59TCr 7.26TCr 13TCr 8,90500Cr 14TCr 88TCr 35TCr 4,29600Cr 37TCr 36TCr P/E ratio 2025
31.3x
P/E ratio 2026 * 31.2x
Enterprise value 14,19500Cr 9.24TCr 7.81TCr 7.14TCr 6.83TCr 13TCr 8,37700Cr 13TCr 83TCr 33TCr 4,04000Cr 35TCr 34TCr EV / Sales 2025
10.4x
EV / Sales 2026 * 10.5x
Free-Float
38.09%
Yield 2025
3.3%
Yield 2026 * 1.53%
1 day+1.82%
1 week+1.49%
Current month+6.09%
1 month+13.48%
3 months+12.49%
6 months+49.15%
Current year+13.27%
1 week 9,038
Extreme 9038
9,342
1 month 8,168
Extreme 8168
9,460
Current year 8,168
Extreme 8168
9,460
1 year 5,942
Extreme 5942
9,460
3 years 3,203
Extreme 3203
9,460
5 years 3,191
Extreme 3191
9,460
10 years 1,003.33
Extreme 1003.3333
9,460
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2021
Director of Finance/CFO - 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 01/03/1993
Director/Board Member 81 01/03/2015
Director/Board Member 77 01/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
+1.82%+1.49%+26.11%+161.54% 9.95TCr
-0.38%+1.08%+22.72%+215.48% 93TCr
-0.05%+2.09%+55.83%+51.71% 59TCr
+0.59%+4.68%+20.73%+53.90% 41TCr
+2.16%+5.16%+25.45%+32.23% 38TCr
+2.39%+9.59%+32.51%+35.14% 32TCr
+1.52%+6.10%+34.09%+59.90% 31TCr
+0.13%+3.77%+46.45%+11.00% 30TCr
+0.73%-1.60%-45.57%-37.14% 22TCr
+1.13%+2.39%+28.23%+55.22% 20TCr
Average +1.00%+2.67%+24.65%+63.90% 37.51TCr
Weighted average by Cap. +0.67%+2.55%+28.08%+84.52%

Financials

2025 2026 *
Net sales 1,24700Cr 811.71Cr 686.3Cr 626.75Cr 600.01Cr 1.11TCr 74TCr 1.15TCr 7.31TCr 2.9TCr 35TCr 3.04TCr 2.98TCr 1,34200Cr 873.73Cr 738.74Cr 674.64Cr 645.86Cr 1.19TCr 79TCr 1.24TCr 7.87TCr 3.12TCr 38TCr 3.28TCr 3.21TCr
Net income 43TCr 278.69Cr 235.63Cr 215.19Cr 206.01Cr 380.58Cr 25TCr 394.54Cr 2.51TCr 994.08Cr 12TCr 1.05TCr 1.02TCr 48TCr 315.08Cr 266.4Cr 243.29Cr 232.91Cr 430.28Cr 29TCr 446.06Cr 2.84TCr 1.12TCr 14TCr 1.18TCr 1.16TCr
Net Debt -90TCr -583.41Cr -493.28Cr -450.48Cr -431.26Cr -796.73Cr -53TCr -825.94Cr -5.25TCr -2.08TCr -26TCr -2.19TCr -2.14TCr -1,03100Cr -671.15Cr -567.46Cr -518.23Cr -496.12Cr -916.55Cr -61TCr -950.15Cr -6.05TCr -2.39TCr -29TCr -2.52TCr -2.47TCr
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,026
Date Price Change Volume
18/26/18 9,337.00 ¥ +1.82% 5,45,700
17/26/17 9,170.00 ¥ -1.21% 21,14,200
16/26/16 9,282.00 ¥ +0.02% 15,26,100
13/26/13 9,280.00 ¥ +0.87% 34,29,500
12/26/12 9,200.00 ¥ +1.97% 23,81,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
9,170.00JPY
Average target price
9,280.00JPY
Spread / Average Target
+1.20%

Quarterly revenue - Rate of surprise